Flatlander schreef op 10 juni 2020 23:56:
BL
The U.S. commercialization is the responsibility of ImmunExpress and not BCART. Part of the private financing round they did in early October last year was to staff up for this launch. You are right that technicians could be a limiting factor. But Immunexpress has advertised training sessions which they conduct with their people. I think a certain amount of cross training has occurred between BCART and ImmunExpress. ImmunExpress took the lead on all of the ISO certification, so I think their working knowledge of Idylla is pretty strong.
There are about 5000 hospitals in the U.S. Assuming they can achieve 10% penetration (500 units) would go along ways toward my projection. Much of this depends on the timing of FDA approvals relative to a pandemic 2nd wave and the results of the COVID/Sepsis validation (yes, I'm certain there will be significant pandemic in the fall).
Jane Papadaki Markley, is the ImmunExpress VP in charge of the commercialization in the U.S. Here is her PR statement.
www.prnewswire.com/news-releases/immu...ImmunExpress presented Idylla data at the 40th International Critical care Conference in March (P482). The results looked good across all demographic groups. I anticipate that the results of the COVID 19 -Sepsis validation will be much more important in driving sales as a triage assay.
Regards FL